Drugs / DS-1103a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05765851 | May 2023 → May 2030 expected | neoplasm | Daiichi Sankyo | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-1103a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05765851 ↗ |
| Action | Inhibit | “designed to block the SIRPα-CD47 interaction” NCT05765851 ↗ |
| Modality | Monoclonal antibody | “a recombinant humanized IgG4 anti-SIRPα antibody” NCT05765851 ↗ |
| Route | Intravenous | “Participants with HER2-expressing or HER2-mutated advanced metastatic solid tumors who will receive an escalating intravenous (IV) infusion of DS-1103a” NCT05765851 ↗ |